Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison Stopeck(National Cancer Centre Japan), Ada Braun(National Cancer Centre Japan), Guenther G. Steger(Mount Vernon Hospital), Roger Dansey(Memorial Sloan Kettering Cancer Center), Qi Jiang(National Cancer Centre Japan), Yasuhiro Fujiwara(Yokohama City University), María Eugenia Ibarrarán Viniegra(National Cancer Centre Japan), Richard H. De Boer(National Cancer Centre Japan), Susie Jun(Ellis Hospital), Jean-Jacques Body(National Cancer Centre Japan), Allan Lipton(National Cancer Centre Japan), Michelle Fan(National Cancer Centre Japan), Katia Tonkin(National Cancer Centre Japan), Mikhail Lichinitser(National Cancer Centre Japan), Denise A. Yardley(Sarah Cannon)
Cited by 1,590
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
An antitumor promoter from Moringa oleifera Lam.
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|1999|404